2026/01/10 更新

所属以外の情報はresearchmapへの登録情報を転載しています。

写真a

タムラ ジュン
田村 惇
Jun Tamura
所属
医学研究科 医科学専攻 臨床統計学 助教
医学部 医学科
職名
助教
外部リンク

研究キーワード

  • 統計科学

  • 生物統計学

研究分野

  • 情報通信 / 統計科学

学歴

  • 横浜市立大学   大学院医学研究科

    2022年4月 - 2025年9月

      詳細を見る

経歴

  • 横浜市立大学   医学部 臨床統計学教室,助教

    2025年10月 - 現在

      詳細を見る

論文

  • Bayesian method for comparing F1 scores in the absence of a gold standard. 査読 国際誌

    Jun Tamura, Yusuke Saigusa, Junichi Fujita, Kouji Yamamoto

    Journal of biopharmaceutical statistics   1 - 11   2025年1月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In the field of medicine, evaluating the diagnostic performance of new diagnostic methods can be challenging, especially in the absence of a gold standard. This study proposes a methodology for assessing the performance of diagnostic tests by estimating the posterior distribution of the F1 score using latent class analysis, without relying on a gold standard. The proposed method utilizes Markov Chain Monte Carlo sampling to estimate the posterior distribution of the F1 score, enabling a comprehensive evaluation of diagnostic test methods. By applying this method to internet addiction, we demonstrate how latent class analysis can be effectively used to assess diagnostic performance, offering a practical solution for situations where no gold standard is available. The effectiveness of the proposed approach was evaluated through simulation studies by examining the coverage probability of the 95% highest density interval of the estimated posterior distributions.

    DOI: 10.1080/10543406.2025.2450319

    PubMed

    researchmap

  • Asymptotic Properties of Matthews Correlation Coefficient. 査読 国際誌

    Yuki Itaya, Jun Tamura, Kenichi Hayashi, Kouji Yamamoto

    Statistics in medicine   44 ( 1-2 )   e10303   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Evaluating classifications is crucial in statistics and machine learning, as it influences decision-making across various fields, such as patient prognosis and therapy in critical conditions. The Matthews correlation coefficient (MCC), also known as the phi coefficient, is recognized as a performance metric with high reliability, offering a balanced measurement even in the presence of class imbalances. Despite its importance, there remains a notable lack of comprehensive research on the statistical inference of MCC. This deficiency often leads to studies merely validating and comparing MCC point estimates-a practice that, while common, overlooks the statistical significance and reliability of results. Addressing this research gap, our paper introduces and evaluates several methods to construct asymptotic confidence intervals for the single MCC and the differences between MCCs in paired designs. Through simulations across various scenarios, we evaluate the finite-sample behavior of these methods and compare their performances. Furthermore, through real data analysis, we illustrate the potential utility of our findings in comparing binary classifiers, highlighting the possible contributions of our research in this field.

    DOI: 10.1002/sim.10303

    PubMed

    researchmap

  • Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). 査読

    Naohiro Okano, Manabu Kawai, Makoto Ueno, Xianjun Yu, Yosuke Inoue, Shinichiro Takahashi, Wenquan Wang, Hidenori Takahashi, Yukiyasu Okamura, Soichiro Morinaga, Ippei Matsumoto, Yasuhiro Shimizu, Kazuhiro Yoshida, Tomohisa Yamamoto, Masayuki Ohtsuka, Yoshikuni Inokawa, Satoshi Nara, Jun Tamura, Satoru Shinoda, Kouji Yamamoto, Hiroki Yamaue, Junji Furuse

    Journal of hepato-biliary-pancreatic sciences   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The efficacy and safety of conversion surgery (CS) after FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) chemotherapy in patients with initially unresectable pancreatic cancer (PC) remains unclear. METHODS: This multicenter retrospective cohort study enrolled patients, between 2014 and 2018, with initially locally advanced or metastatic PC who were considered candidates for CS following FOLFIRINOX or GnP chemotherapy. They were classified into surgery (207 patients [194 resection and 13 exploratory laparotomy only]) and continued chemotherapy (10 patients, control) groups. The primary endpoint was overall survival (OS) from the day of diagnosis of potentially curative resection on imaging studies, with an expected hazard ratio (HR) of 0.7. RESULTS: OS in the surgery group was longer than that in the control group (HR, 0.47; 95% confidence interval [CI]: 0.24-0.93). The median OS was 34.4 (95% CI: 27.9-43.4) and 19.8 (95% CI: 14.9-31.1) months in the surgery and control groups, respectively. The Clavien-Dindo grade ≥ IIIa postoperative complication and in-hospital mortality rates were 19.6% and 0.5%, respectively. Multivariate analysis revealed that preoperative chemotherapy duration was not associated with OS. CONCLUSIONS: CS, following a favorable response to FOLFIRINOX or GnP chemotherapy, improved initially unresectable PC prognosis (specifically, OS), regardless of the chemotherapy duration.

    DOI: 10.1002/jhbp.12066

    PubMed

    researchmap

  • Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients. 査読 国際誌

    Tomoya Watanabe, Yasushi Ototake, Asami Akita, Mao Suzuki, Miwa Kanaoka, Jun Tamura, Yusuke Saigusa, Yukie Yamaguchi

    Arthritis research & therapy   26 ( 1 )   93 - 93   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Anti-SS-A/Ro antibody (anti-SSA), the diagnostic marker of Sjögren's syndrome (SS), is often detected in systemic sclerosis (SSc). Some patients are diagnosed with SSc/SS overlap syndromes, while there are anti-SSA-positive SSc cases without SS. In this study, we investigated the clinical characteristics of SSc with anti-SSA and clarified the clinical impact of this antibody in SSc. METHODS: A retrospective chart review was conducted of 156 patients with SSc at Yokohama City University Hospital from 2018 to 2021. Clinical data, laboratory data, imaging, and autoantibody positivity status were collected and analysed to assess the association between these variables and anti-SSA using multivariable logistic regression analysis. RESULTS: This cohort included 18 men and 138 women with SSc (median age, 69.0 years). Thirty-nine patients had diffuse cutaneous SSc (dcSSc) (25%), and 117 patients had limited cutaneous SSc (75%). Forty-four patients were anti-SSA-positive. Among them, 24 fulfilled the SS criteria. Multivariable logistic regression revealed that anti-SSA was statistically associated with interstitial lung disease (ILD; odds ratio [OR] = 2.67; 95% confidence interval [CI], 1.14-6.3; P = 0.024). Meanwhile, anti-SSA positivity tended to increase the development of digital ulcer (OR = 2.18; 95% CI, 0.99-4.82, P = 0.054). In the comparative analysis of the autoantibody single-positive and anti-SSA/SSc-specific autoantibody double-positive groups, the anti-SSA single-positive group showed a significantly increased risk of ILD (OR = 12.1; 95% CI, 2.13-140.57; P = 0.003). Furthermore, patients with SSc and anti-SSA indicated that anti-SSA-positive SSc without SS was strongly associated with dcSSc when compared to that in patients with SS (OR = 6.45; 95% CI, 1.23-32.60; P = 0.024). CONCLUSIONS: Anti-SSA positivity increases the risk of organ involvement, such as ILD, in patients with SSc. Additionally, the anti-SSA-positive SSc without SS population may have more severe skin fibrosis than others. Anti-SSA may be a potential marker of ILD and skin severity in SSc.

    DOI: 10.1186/s13075-024-03325-6

    PubMed

    researchmap

  • Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study. 査読

    Shoji Nagao, Jun Tamura, Takashi Shibutani, Maiko Miwa, Tomoyasu Kato, Ayumi Shikama, Yuji Takei, Natsuko Kamiya, Naoki Inoue, Kazuto Nakamura, Aya Inoue, Koji Yamamoto, Keiichi Fujiwara, Mitsuaki Suzuki

    International journal of clinical oncology   28 ( 6 )   804 - 815   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Three randomized controlled trials have resulted in extremely extensive application of the strategy of using neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for patients with advanced epithelial ovarian cancer in Japan. This study aimed to evaluate the status and effectiveness of treatment strategies using NAC followed by IDS in Japanese clinical practice. PATIENTS AND METHODS: We conducted a multi-institutional observational study of 940 women with Federation of Gynecology and Obstetrics (FIGO) stages III-IV epithelial ovarian cancer treated at one of nine centers between 2010 and 2015. Progression-free survival (PFS) and overall survival (OS) were compared between 486 propensity-score matched participants who underwent NAC followed by IDS and primary debulking surgery (PDS) followed by adjuvant chemotherapy. RESULTS: Patients with FIGO stage IIIC receiving NAC had a shorter OS (median OS: 48.1 vs. 68.2 months, hazard ratio [HR]: 1.34; 95% confidence interval [CI] 0.99-1.82, p = 0.06) but not PFS (median PFS: 19.7 vs. 19.4 months, HR: 1.02; 95% CI: 0.80-1.31, p = 0.88). However, patients with FIGO stage IV receiving NAC and PDS had comparable PFS (median PFS: 16.6 vs. 14.7 months, HR: 1.07 95% CI: 0.74-1.53, p = 0.73) and OS (median PFS: 45.2 vs. 35.7 months, HR: 0.98; 95% CI: 0.65-1.47, p = 0.93). CONCLUSIONS: NAC followed by IDS did not improve survival. In patients with FIGO stage IIIC, NAC may be associated with a shorter OS.

    DOI: 10.1007/s10147-023-02329-7

    PubMed

    researchmap

  • Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registry. 査読 国際誌

    Chiharu Hidekawa, Ryusuke Yoshimi, Yusuke Saigusa, Jun Tamura, Noriko Kojitani, Naoki Suzuki, Natsuki Sakurai, Yuji Yoshioka, Yumiko Sugiyama-Kawahara, Yosuke Kunishita, Daiga Kishimoto, Kana Higashitani, Yuichiro Sato, Takaaki Komiya, Hideto Nagai, Naoki Hamada, Ayaka Maeda, Naomi Tsuchida, Lisa Hirahara, Yutaro Soejima, Kaoru Takase-Minegishi, Yohei Kirino, Nobuyuki Yajima, Ken-Ei Sada, Yoshia Miyawaki, Kunihiro Ichinose, Shigeru Ohno, Hiroshi Kajiyama, Shuzo Sato, Yasuhiro Shimojima, Michio Fujiwara, Hideaki Nakajima

    Frontiers in immunology   14   1227403 - 1227403   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Infection is a leading cause of death in patients with systemic lupus erythematosus (SLE). Alt hough hydroxychloroquine (HCQ) has been reported to inhibit infection, evidence from Asian populations remains insufficient. We investigated this effect in Japanese SLE patients. METHODS: Data from the Lupus Registry of Nationwide Institutions were used in this study. The patients were ≥20 years old and met the American College of Rheumatology (ACR) classification criteria revised in 1997. We defined "severe infections" as those requiring hospitalization. We analyzed the HCQ's effect on infection suppression using a generalized estimating equation (GEE) logistic regression model as the primary endpoint and performed a survival analysis for the duration until the first severe infection. RESULTS: Data from 925 patients were used (median age, 45 [interquartile range 35-57] years; female, 88.1%). GEE analysis revealed that severe infections were significantly associated with glucocorticoid dose (odds ratio [OR] 1.968 [95% confidence interval, 1.379-2.810], p<0.001), immunosuppressants (OR 1.561 [1.025-2.380], p=0.038), and baseline age (OR 1.043 [1.027-1.060], p<0.001). HCQ tended to suppress severe infections, although not significantly (OR 0.590 [0.329-1.058], p=0.077). Survival time analysis revealed a lower incidence of severe infections in the HCQ group than in the non-HCQ group (p<0.001). In a Cox proportional hazards model, baseline age (hazard ratio [HR] 1.029 [1.009-1.050], p=0.005) and HCQ (HR 0.322 [0.142-0.728], p=0.006) were significantly related to incidence. CONCLUSION: HCQ may help extend the time until the occurrence of infection complications and tends to decrease infection rates.

    DOI: 10.3389/fimmu.2023.1227403

    PubMed

    researchmap

  • Phase II Study of a Multi-center Randomized Controlled Trial to Evaluate Oral Vitamin B12 Treatment for Vitamin B12 Deficiency After Total Gastrectomy in Gastric Cancer Patients. 査読 国際誌

    Toru Aoyama, Yukio Maezawa, Haruhiko Cho, Yusuke Saigusa, Jun Tamura, Kazuhito Tsuchida, Keisuke Komori, Kazuki Kano, Kenki Segami, Kentaro Hara, Kotaro Senuki, Yoshihiro Suzuki, Michiyo Yamakawa, Hiroshi Tamagawa, Takashi Oshima, Norio Yukawa, Yasushi Rino

    Anticancer research   42 ( 8 )   3963 - 3970   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: This prospective multi-central randomized phase II trial evaluated the efficacy and safety of oral Vitamin B12 500 μg/day replacement compared with oral Vitamin B12 1,500 μg/day in patients with Vitamin B12 deficiency after total gastrectomy for gastric cancer. PATIENTS AND METHODS: Patients were randomly assigned to receive oral Vitamin B12 500 μg/day or Vitamin B12 1,500 μg/day in a 1:1 ratio with a minimization method. The primary endpoint was the incidence of a normal serum Vitamin B12 level at three months after treatment. RESULTS: From January 2018 to December 2021, 3 institutions collaborated with the present study, and 74 patients were registered from these 3 institutions. The study was prematurely closed due to poor accrual after reaching almost 50% of its goal. Among the 74 recruited patients, 36 were allocated to the Vitamin B12 500 μg/day arm and 38 to Vitamin B12 1,500 μg/day arm. The incidences of patients with a normal Vitamin B12 level at 3 months (serum Vitamin B12 level >200 pg/ml) were 91.7% (33/36) in the Vitamin B12 500 μg/day arm and 100% (38/38) in the Vitamin B12 1,500 μg/day arm (p=0.3587). The types of clinical symptoms with Vitamin B12 deficiency that improved with Vitamin B12 treatment and the degree of improvement were also similar. CONCLUSION: Although the primary endpoint of the present study was not met, it was found that oral Vitamin B12 500 μg/day replacement is as effective and safe as oral Vitamin B12 1,500 μg/day replacement for Vitamin B12 deficiency.

    DOI: 10.21873/anticanres.15891

    PubMed

    researchmap

  • Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. 国際誌

    Shiting Xu, Takehito Shukuya, Jun Tamura, Shoko Shimamura, Kana Kurokawa, Keita Miura, Taichi Miyawaki, Daisuke Hayakawa, Tetsuhiko Asao, Kouji Yamamoto, Kazuhisa Takahashi

    JTO clinical and research reports   3 ( 4 )   100309 - 100309   2022年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Outcomes of immune checkpoint inhibitor (ICI) rechallenge in NSCLC remain uncertain. This study estimated the safety and efficacy of ICI rechallenge and compared rechallenge benefit among different reasons of initial ICI discontinuation in NSCLC. METHODS: PubMed, EMBASE, and Cochrane Library were searched for studies on NSCLC retreated with ICI. Immune-related adverse events (irAEs), overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) at initial ICI and rechallenge were analyzed. RESULTS: A total of 15 studies including 442 patients between 2018 and 2022 were eligible for meta-analysis. The incidence of grade 3 or 4 irAE was lower in rechallenge than initial ICI (8.6% versus 17.8%, p < 0.001). Patients rechallenged with ICI had lower ORR and DCR than initial ICI (13.2% versus 42.4%, p < 0.001; 51.1% versus 74.0%, p < 0.001). The ORR and DCR to ICI rechallenge were both higher in patients who experienced disease progression after stopping ICI or irAE than patients with disease progression during ICI treatment (ORR: 46.2% versus 20% versus 11.4%, p = 0.003; DCR: 84.6% versus 90.0% versus 55.0%, p = 0.002). In addition, 34.7% of 69 patients with individual response to ICI and PFS experienced the same or better response to ICI rechallenge in comparison with initial ICI, although PFS in initial ICI was longer than that in ICI rechallenge (median: 8.90 versus 3.67 mo, hazard ratio = 0.44, 95% confidence interval: 0.33-0.59). CONCLUSIONS: ICI rechallenge had less severe toxicity than initial ICI treatment. Patients undergoing disease progression after ICI cessation or ICI discontinuation owing to irAE are more likely to benefit from ICI rechallenge in NSCLC.

    DOI: 10.1016/j.jtocrr.2022.100309

    PubMed

    researchmap

▼全件表示

MISC

  • A Directional Measure of Marginal Inhomogeneity for Square Contingency Tables using Discrete-time hazard

    Jun Tamura, Satoru Shinoda

    2025年4月

     詳細を見る

    In the analysis of square contingency tables with ordered categories, it is
    essential to assess deviations from marginal homogeneity (MH) when marginal
    equivalency between row and column variables does not hold. Some measures for
    evaluating the degree of departure from the MH model have been proposed. This
    study proposes a new directional measure using the discrete-time hazard,
    assuming that categories represent discrete time points. The proposed measure
    is capable of capturing both the magnitude and direction of deviation from the
    MH model. It is defined on a continuous scale from $-1$ to $1$, which allows
    for intuitive interpretation of the nature of marginal change.
    An estimator of the proposed measure and an asymptotic confidence interval
    are derived using the delta method. The theoretical properties of the measure
    are also discussed. The proposed measure provides a flexible tool for
    characterizing marginal inhomogeneity in square contingency tables under
    ordinal settings.

    arXiv

    researchmap

    その他リンク: http://arxiv.org/pdf/2504.18100v1

  • Statistical Inference of the Matthews Correlation Coefficient for Multiclass Classification

    Jun Tamura, Yuki Itaya, Kenichi Hayashi, Kouji Yamamoto

    2025年3月

     詳細を見る

    Classification problems are essential statistical tasks that form the
    foundation of decision-making across various fields, including patient
    prognosis and treatment strategies for critical conditions. Consequently,
    evaluating the performance of classification models is of significant
    importance, and numerous evaluation metrics have been proposed. Among these,
    the Matthews correlation coefficient (MCC), also known as the phi coefficient,
    is widely recognized as a reliable metric that provides balanced measurements
    even in the presence of class imbalance. However, with the increasing
    prevalence of multiclass classification problems involving three or more
    classes, macro-averaged and micro-averaged extensions of MCC have been
    employed, despite a lack of clear definitions or established references for
    these extensions. In the present study, we propose a formal framework for MCC
    tailored to multiclass classification problems using macro-averaged and
    micro-averaged approaches. Moreover, discussions on the use of these extended
    MCCs for multiclass problems often rely solely on point estimates, potentially
    overlooking the statistical significance and reliability of the results. To
    address this gap, we introduce several methods for constructing asymptotic
    confidence intervals for the proposed metrics. Furthermore, we extend these
    methods to include the construction of asymptotic confidence intervals for
    differences in the proposed metrics, specifically for paired study designs. The
    utility of our methods is evaluated through comprehensive simulations and
    real-world data analyses.

    arXiv

    researchmap

    その他リンク: http://arxiv.org/pdf/2503.06450v1

講演・口頭発表等

  • A Bayesian method for comparing F1 scores in the absence of a Gold standard

    田村惇, 三枝祐輔, 山本紘司

    2021年度日本分類学会シンポジウム  2021年12月 

     詳細を見る

  • 潜在クラスモデルを用いたF1スコアによる検査法の性能比較

    田村惇, 三枝祐輔, 山本紘司

    日本計算機統計学会第36回大会  2022年5月 

     詳細を見る

  • 確定診断が存在しない疾患に対する検査の評価方法

    田村惇, 三枝祐輔, 山本紘司

    第2回かごしまデータ科学シンポジウム  2022年7月 

     詳細を見る

  • Asymptotic properties of the Matthews correlation coefficient

    Yuki Itaya, Jun Tamura, Kenichi Hayashi, Kouji Yamamoto

    The 8th Japanese-German Symposium on Classification  2023年10月 

     詳細を見る

  • 正方分割表におけるcontinuation oddを用いた周辺非同等性の尺度:対応のある離散時間データへの適応を目指して

    田村惇, 篠田覚

    第6回かごしまデータ科学シンポジウム  2024年8月 

     詳細を見る

  • マシューズ相関係数の多値分類問題に対する拡張と統計的推測

    田村惇, 板谷勇輝, 林賢一, 山本紘司

    2024年統計関連学会連合大会  2024年9月 

     詳細を見る

  • Statistical Inference for the Matthews Correlation Coefficient in Multiclass Classification

    Jun Tamura, Yuki Itaya, Kenichi Hayashi, Kouji Yamamoto

    ENAR 2025 Spring Meeting  2025年3月 

     詳細を見る

  • Evaluating Diagnostic Performance via Bayesian F1 Score Estimation without a Gold Standard

    BIBC 2025  2025年11月 

     詳細を見る

  • ベイズ流アプローチを用いたゴールドスタンダードが存在しない検査法のF1スコアによる性能評価

    田村惇, 三枝祐輔, 山本紘司

    第16回Biostatistics Network  2021年9月 

     詳細を見る

▼全件表示

受賞

  • Student Poster Prize

    2025年   Biometrics in the Bush Capital  

     詳細を見る